Given the opposite results between hyper- and hypoadiponectinemia on renal progression, cardiovascular outcomes, or metabolic disturbance-related disease, we have clarified the scope between circulating adiponectin levels and metabolic syndrome using a well-established chronic kidney disease cohort database. This evidence concerns the gene ADIPOQ and metabolic syndrome.